Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study.
Matasar, M Herrera, A Kamdar, M Mehta, A Assouline, S Fleury, I Kim, T Kim, W Bosch, F Radford, John A
Matasar, M
Herrera, A
Kamdar, M
Mehta, A
Assouline, S
Fleury, I
Kim, T
Kim, W
Bosch, F
Radford, John A
Citations
Altmetric:
Abstract
Description
Lymphoma Research Team
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study. 2017, 102:173-173 Haematologica